Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

Science Signaling

Volumn 8, Issue 379, 2015, Pages

  Mancini, Maicol ^a   Gaborit, Nadège ^a   Lindzen, Moshit ^a   Salame, Tomer Meir ^a   Dall'Ora, Massimiliano ^a   Sevilla Sharon, Michal ^a   Abdul Hai, Ali ^a,b   Downward, Julian ^c,d   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 111; MONOCLONAL ANTIBODY 12; MONOCLONAL ANTIBODY 252; MONOCLONAL ANTIBODY 26; MONOCLONAL ANTIBODY 33; MONOCLONAL ANTIBODY 565; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; CANCER ANTIBODY; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN;

ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; LONG TERM EXPOSURE; LUNG CANCER; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930518226     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aaa0725     Document Type: Article

References (58)

1. R. Siegel, J. Ma, Z. Zou, A. Jemal, Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
2. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman, D. A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
3. J. G. Paez, P. A. Jänne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson, M. Meyerson, EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
4. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, H. Varmus, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 101, 13306-13311 (2004).
5. Y. Yarden, G. Pines, The ERBB network: At last, cancer therapy meets systems biology. Nat. Rev. Cancer 12, 553-563 (2012).
6. neu protein and EGF receptor modulates EGF receptor function. Cell 61, 1339-1347 (1990).
7. R. Goldman, R. B. Levy, E. Peles, Y. Yarden, Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation. Biochemistry 29, 11024-11028 (1990).
8. T. S. Mok, Y. L. Wu, S. Thongprasert, C. H. Yang, D. T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J. J. Yang, B. Chewaskulyong, H. Jiang, E. L. Duffield, C. L. Watkins, A. A. Armour, M. Fukuoka, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
9. R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, C. Camps, M. Majem, G. Lopez-Vivanco, D. Isla, M. Provencio, A. Insa, B. Massuti, J. L. Gonzalez-Larriba, L. Paz-Ares, I. Bover, R. Garcia-Campelo, M. A. Moreno, S. Catot, C. Rolfo, N. Reguart, R. Palmero, J. M. Sánchez, R. Bastus, C. Mayo, J. Bertran-Alamillo, M. A. Molina, J. J. Sanchez, M. Taron; Spanish Lung Cancer Group, Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958-967 (2009).
10. G. R. Oxnard, M. E. Arcila, J. Chmielecki, M. Ladanyi, V. A. Miller, W. Pao, New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin. Cancer Res. 17, 5530-5537 (2011).
11. W. Pao, V. A. Miller, K. A. Politi, G. J. Riely, R. Somwar, M. F. Zakowski, M. G. Kris, H. Varmus, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLOS Med. 2, e73 (2005).
12. S. Kobayashi, T. J. Boggon, T. Dayaram, P. A. Jänne, O. Kocher, M. Meyerson, B. E. Johnson, M. J. Eck, D. G. Tenen, B. Halmos, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005).
13. J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C. -M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Jänne, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
14. J. Bean, C. Brennan, J. Y. Shih, G. Riely, A. Viale, L. Wang, D. Chitale, N. Motoi, J. Szoke, S. Broderick, M. Balak, W. C. Chang, C. J. Yu, A. Gazdar, H. Pass, V. Rusch, W. Gerald, S. F. Huang, P. C. Yang, V. Miller, M. Ladanyi, C. H. Yang, W. Pao, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U. S. A. 104, 20932-20937 (2007).
15. J. A. Engelman, P. A. Jänne, Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14, 2895-2899 (2008).
16. F. Yamasaki, M. J. Johansen, D. Zhang, S. Krishnamurthy, E. Felix, C. Bartholomeusz, R. J. Aguilar, K. Kurisu, G. B. Mills, G. N. Hortobagyi, N. T. Ueno, Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 67, 5779-5788 (2007).
17. K. Ohashi, Y. E. Maruvka, F. Michor, W. Pao, Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J. Clin. Oncol. 31, 1070-1080 (2013).
18. F. R. Hirsch, P. A. Jänne, W. E. Eberhardt, F. Cappuzzo, N. Thatcher, R. Pirker, H. Choy, E. S. Kim, L. Paz-Ares, D. R. Gandara, Y. L. Wu, M. J. Ahn, T. Mitsudomi, F. A. Shepherd, T. S. Mok, Epidermal growth factor receptor inhibition in lung cancer: Status 2012. J. Thorac. Oncol. 8, 373-384 (2013).
19. G. M. Keating, Afatinib: A review of its use in the treatment of advanced non-small cell lung cancer. Drugs 74, 207-221 (2014).
20. L. Regales, Y. Gong, R. Shen, E. de Stanchina, I. Vivanco, A. Goel, J. A. Koutcher, M. Spassova, O. Ouerfelli, I. K. Mellinghoff, M. F. Zakowski, K. A. Politi, W. Pao, Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 119, 3000-3010 (2009).
21. Y. Y. Janjigian, E. F. Smit, H. J. M. Groen, L. Horn, S. Gettinger, D. R. Camidge, G. J. Riely, B. Wang, Y. Fu, V. K. Chand, V. A. Miller, W. Pao, Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov. 4, 1036-1045 (2014).
22. V. Pirazzoli, C. Nebhan, X. Song, A. Wurtz, Z. Walther, G. Cai, Z. Zhao, P. Jia, E. de Stanchina, E. M. Shapiro, M. Gale, R. Yin, L. Horn, D. P. Carbone, P. J. Stephens, V. Miller, S. Gettinger, W. Pao, K. Politi, Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep. 7, 999-1008 (2014).
23. B. C. Liao, C. C. Lin, J. C. Yang, Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr. Opin. Oncol. 27, 94-101 (2015).
24. R. Pirker, J. R. Pereira, A. Szczesna, J. von Pawel, M. Krzakowski, R. Ramlau, I. Vynnychenko, K. Park, C. T. Yu, V. Ganul, J. K. Roh, E. Bajetta, K. O'Byrne, F. de Marinis, W. Eberhardt, T. Goddemeier, M. Emig, U. Gatzemeier; FLEX Study Team, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373, 1525-1531 (2009).
25. T. J. Lynch, T. Patel, L. Dreisbach, M. McCleod, W. J. Heim, R. C. Hermann, E. Paschold, N. O. Iannotti, S. Dakhil, S. Gorton, V. Pautret, M. R. Weber, D. Woytowitz, Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J. Clin. Oncol. 28, 911-917 (2010).
26. F. R. Hirsch, M. Varella-Garcia, F. Cappuzzo, Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28 (Suppl. 1), S32-S37 (2009).
27. F. R. Hirsch, M. Varella-Garcia, P. A. Bunn Jr., W. A. Franklin, R. Dziadziuszko, N. Thatcher, A. Chang, P. Parikh, J. R. Pereira, T. Ciuleanu, J. von Pawel, C. Watkins, A. Flannery, G. Ellison, E. Donald, L. Knight, D. Parums, N. Botwood, B. Holloway, Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24, 5034-5042 (2006).
28. R. Pirker, J. R. Pereira, J. von Pawel, M. Krzakowski, R. Ramlau, K. Park, F. deMarinis, W. E. E. Eberhardt, L. Paz-Ares, S. Störkel, K.-M. Schumacher, A. von Heydebreck, I. Celik, K. J. O'Byrne, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol. 13, 33-42 (2012).
29. R. Pirker, J. R. Pereira, A. Szczesna, J. von Pawel, M. Krzakowski, R. Ramlau, I. Vynnychenko, K. Park, W. E. Eberhardt, F. de Marinis, S. Heeger, T. Goddemeier, K. J. O'Byrne, U. Gatzemeier, Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study. Lung Cancer 77, 376-382 (2012).
30. F. R. Hirsch, R. S. Herbst, C. Olsen, K. Chansky, J. Crowley, K. Kelly, W. A. Franklin, P. A. Bunn Jr., M. Varella-Garcia, D. R. Gandara, Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J. Clin. Oncol. 26,3351-3357 (2008).
31. T. Takano, Y. Ohe, H. Sakamoto, K. Tsuta, Y. Matsuno, U. Tateishi, S. Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, T. Shibata, T. Sakiyama, T. Yoshida, T. Tamura, Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23, 6829-6837 (2005).
32. E. C. de Bruin, C. Cowell, P. H. Warne, M. Jiang, R. E. Saunders, M. A. Melnick, S. Gettinger, Z. Walther, A. Wurtz, G. J. Heynen, D. A. Heideman, J. Gómez-Román, A. García-Castaño, Y. Gong, M. Ladanyi, H. Varmus, R. Bernards, E. F. Smit, K. Politi, J. Downward, Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 4, 606-619 (2014).
33. J. Cho, L. Chen, N. Sangji, T. Okabe, K. Yonesaka, J. M. Francis, R. J. Flavin, W. Johnson, J. Kwon, S. Yu, H. Greulich, B. E. Johnson, M. J. Eck, P. A. Jänne, K. K. Wong, M. Meyerson, Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 73, 6770-6779 (2013).
34. R. Maron, B. Schechter, M. Mancini, G. Mahlknecht, Y. Yarden, M. Sela, Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc. Natl. Acad. Sci. U.S.A. 110, 15389-15394 (2013).
35. D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, Y. Yarden, Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc. Natl. Acad. Sci. U.S.A. 110, 1815-1820 (2013).
36. T. Ben-Kasus, B. Schechter, S. Lavi, Y. Yarden, M. Sela, Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc. Natl. Acad. Sci. U.S.A. 106, 3294-3299 (2009).
37. L. M. Friedman, A. Rinon, B. Schechter, L. Lyass, S. Lavi, S. S. Bacus, M. Sela, Y. Yarden, Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 102, 1915-1920 (2005).
38. J. B. Spangler, J. R. Neil, S. Abramovitch, Y. Yarden, F. M. White, D. A. Lauffenburger, K. D. Wittrup, Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc. Natl. Acad. Sci. U.S.A. 107, 13252-13257 (2010).
39. V. Serra, M. Scaltriti, L. Prudkin, P. J. Eichhorn, Y. H. Ibrahim, S. Chandarlapaty, B. Markman, O. Rodriguez, M. Guzman, S. Rodriguez, M. Gili, M. Russillo, J. L. Parra, S. Singh, J. Arribas, N. Rosen, J. Baselga, PI3Kinhibition results in enhanced HER signalingand acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30, 2547-2557 (2011).
40. N. V. Sergina, M. Rausch, D. Wang, J. Blair, B. Hann, K. M. Shokat, M. M. Moasser, Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441 (2007).
41. A. O. Walter, R. T. T. Sjin, H. J. Haringsma, K. Ohashi, J. Sun, K. Lee, A. Dubrovskiy, M. Labenski, Z. Zhu, Z. Wang, M. Sheets, T. St Martin, R. Karp, D. van Kalken, P. Chaturvedi, D. Niu, M. Nacht, R. C. Petter, W. Westlin, K. Lin, S. Jaw-Tsai, M. Raponi, T. Van Dyke, J. Etter, Z. Weaver, W. Pao, J. Singh, A. D. Simmons, T. C. Harding, A. Allen, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 3, 1404-1415 (2013).
42. D. A. E. Cross, S. E. Ashton, S. Ghiorghiu, C. Eberlein, C. A. Nebhan, P. J. Spitzler, J. P. Orme, M. R. V. Finlay, R. A. Ward, M. J. Mellor, G. Hughes, A. Rahi, V. N. Jacobs, M. Red Brewer, E. Ichihara, J. Sun, H. Jin, P. Ballard, K. Al-Kadhimi, R. Rowlinson, T. Klinowska, G. H. P. Richmond, M. Cantarini, D.-W. Kim, M. R. Ranson, W. Pao, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046-1061 (2014).
43. I. Amit, R. Wides, Y. Yarden, Evolvable signaling networks of receptor tyrosine kinases: Relevance of robustness to malignancy and to cancer therapy. Mol. Syst. Biol. 3, 151 (2007).
44. B. N. Kholodenko, J. F. Hancock, W. Kolch, Signalling ballet in space and time. Nat. Rev. Mol. Cell Biol. 11, 414-426 (2010).
45. M. Will, A. C. R. Qin, W. Toy, Z. Yao, V. Rodrik-Outmezguine, C. Schneider, X. Huang, P. Monian, X. Jiang, E. de Stanchina, J. Baselga, N. Liu, S. Chandarlapaty, N. Rosen, Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov. 4, 334-347 (2014).
46. C. Montero-Conde, S. Ruiz-Llorente, J. M. Dominguez, J. A. Knauf, A. Viale, E. J. Sherman, M. Ryder, R. A. Ghossein, N. Rosen, J. A. Fagin, Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 3, 520-533 (2013).
47. T790M mutation. Cancer Discov. 2, 922-933 (2012).
48. K. Shtiegman, B. S. Kochupurakkal, Y. Zwang, G. Pines, A. Starr, A. Vexler, A. Citri, M. Katz, S. Lavi, Y. Ben-Basat, S. Benjamin, S. Corso, J. Gan, R. B. Yosef, S. Giordano, Y. Yarden, Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 26, 6968-6978 (2007).
49. J. L. Pujol, R. Pirker, T. J. Lynch, C. A. Butts, R. Rosell, F. A. Shepherd, J. Vansteenkiste, K. J. O'Byrne, B. de Blas, J. Heighway, A. von Heydebreck, N. Thatcher, Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as firstline treatment for advanced non-small cell lung cancer. Lung Cancer 83, 211-218 (2014).
50. J. C. Yang, V. Hirsh, M. Schuler, N. Yamamoto, K. J. O'Byrne, T. S. Mok, V. Zazulina, M. Shahidi, J. Lungershausen, D. Massey, M. Palmer, L. V. Sequist, Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3342-3350 (2013).
51. C. Larbouret, N. Gaborit, T. Chardès, M. Coelho, E. Campigna, C. Bascoul-Mollevi, J. P. Mach, D. Azria, B. Robert, A. Pèlegrin, In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: Implication of receptors' down-regulation and dimers' disruption. Neoplasia 14, 121-130 (2012).
52. W. Scheuer, T. Friess, H. Burtscher, B. Bossenmaier, J. Endl, M. Hasmann, Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 69, 9330-9336 (2009).
53. J. Baselga, J. Cortés, S. B. Kim, S. A. Im, R. Hegg, Y. H. Im, L. Roman, J. L. Pedrini, T. Pienkowski, A. Knott, E. Clark, M. C. Benyunes, G. Ross, S. M. Swain; CLEOPATRA Study Group, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109-119 (2012).
54. M. W. Pedersen, H. J. Jacobsen, K. Koefoed, A. Hey, C. Pyke, J. S. Haurum, M. Kragh, Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 70, 588-597 (2010).
55. M. Iida, T. M. Brand, D. A. Campbell, M. M. Starr, N. Luthar, A. M. Traynor, D. L. Wheeler, Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol. Ther. 14, 481-491 (2013).
56. C. I. Spiridon, M. A. Ghetie, J. Uhr, R. Marches, J. L. Li, G. L. Shen, E. S. Vitetta, Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 8, 1720-1730 (2002).
57. A. Citri, I. Alroy, S. Lavi, C. Rubin, W. Xu, N. Grammatikakis, C. Patterson, L. Neckers, D. W. Fry, Y. Yarden, Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: Implications for cancer therapy. EMBO J. 21, 2407-2417 (2002).
58. N. Gaborit, A. Abdul-Hai, M. Mancini, M. Lindzen, S. Lavi, O. Leitner, L. Mounier, M. Chentouf, S. Dunoyer, M. Ghosh, C. Larbouret, T. Chardès, H. Bazin, A. Pèlegrin, M. Sela, Y. Yarden, Examination of HER3 targeting in cancer using monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 112, 839-844 (2015).